CD4 and melanoma: Here, analysis of a smaller melanoma cohort (n = 36) did not show any obvious correlation between the proportion of tumor-reactive CD8+ or CD4+ TILs and TMB (Figure 3, data with TCL/TCL + IFNγ only are shown in Figure S9).